Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04625270 · ClinicalTrials.gov registry record · Phase 2
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
A Phase 2 study of Ovarian Cancer and Low Grade Ovarian Serous Adenocarcinoma, sponsored by Verastem.
- Active
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
- 20
- Study locations
NCT04625270: Active Phase 2 study of Ovarian Cancer and Low Grade Ovarian Serous Adenocarcinoma, sponsored by Verastem.
NCT04625270 is a Phase 2 study of Ovarian Cancer and Low Grade Ovarian Serous Adenocarcinoma that is active but no longer recruiting, run by Verastem. The registered enrollment target is 225 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04625270, a Phase 2 study of Ovarian Cancer and Low Grade Ovarian Serous Adenocarcinoma, is active but no longer recruiting, sponsored by Verastem.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Primary Outcome
Confirmed overall response rate per RECIST 1.1
Conditions Studied
Interventions
- DRUG avutometinib (VS-6766)
- DRUG avutometinib (VS-6766) and defactinib
Study Locations (20)
Florida
- Advent Health - Orlando
- H. Lee Moffitt Cancer Center and Research Institute - Center for Women's Oncology - Tampa
Ohio
- Cleveland Clinic Women's Health Institute - Cleveland
- The Ohio State University Wexner Medical Center - Columbus
Oregon
- Willamette Valley Cancer Institute and Research Center - Eugene
- Northwest Cancer Specialists - Portland
Texas
- Texas Oncology Austin Central - Austin
- Texas Oncology- Dallas Presbyterian Hospital - Dallas
Arizona
- Arizona Oncology Associates PC HAL - Scottsdale
California
- Sansum Clinic - Santa Barbara
Connecticut
- Yale School of Medicine - New Haven
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT04625270 still lists
NCT04625270 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which avutometinib (VS-6766) is the first listed.
NCT04625270 names 20 study sites across 16 states, led by Florida, Ohio, Oregon.
Frequently Asked Questions
What is clinical trial NCT04625270 about?
NCT04625270 is a clinical study titled "A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation". This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
What is the current status of trial NCT04625270?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2020-12-21. Estimated completion is 2026-12.
What conditions does trial NCT04625270 study?
This clinical trial studies the following conditions: Ovarian Cancer, Low Grade Ovarian Serous Adenocarcinoma.
What interventions are being tested in trial NCT04625270?
The interventions under investigation include: avutometinib (VS-6766) (DRUG), avutometinib (VS-6766) and defactinib (DRUG).
Who is sponsoring clinical trial NCT04625270?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04625270 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04625270's enrollment target sits among peer trials
225 87th of 322 higher than 236 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI